Allstocks.com's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » .11 and Up! » GTF== Down 60% ---- Cytomedix says FDA unit denies its claim on gel

 - UBBFriend: Email this page to someone!    
Author Topic: GTF== Down 60% ---- Cytomedix says FDA unit denies its claim on gel
Lootcifer
Member


Member Rated:
4
Icon 3 posted      Profile for Lootcifer     Send New Private Message       Edit/Delete Post   Reply With Quote 
Great Bottom Bounce Here........

FDA Denies Cytomedix Gel Marketing Claim
Tuesday October 17, 9:49 am ET
Cytomedix Receives FDA Denial Letter on Marketing Claim for Wound Treatment AutoloGel

ROCKVILLE, Md. (AP) -- Biotechnology company Cytomedix Inc. said Tuesday the Food and Drug Administration denied the company's marketing claim that its AutoloGel wound healing treatment is equivalent to similar treatments on the market.

ADVERTISEMENT
click here
In a statement, the company said the agency's primary grounds for rejecting the claim involve the use of bovine thrombin, a clotting agent derived from cows, to activate the plasma in AutoloGel.

Although bovine thrombin has been used on humans in surgery and other instances to stop bleeding, and is also used along with platelet gel therapy products that have been cleared by FDA for surgical use, complications can involve the creation of antibodies that could cause a bleeding tendency.

No such complications were found either in clinical trials or in medical reviews, the company said.

"The company will immediately pursue an appeal not in an adversarial approach with the agency, but in a consultative mode to assure that the company's position, including the views of additional scientific experts are fully considered by the FDA," Cytomedix said in a statement. The appeals process is expected to be complete in 60 to 90 days.

The company could not be immediately reached for comment early Tuesday morning.

Cytomedix said it met with the FDA in September, where a variety of safety and effectiveness issues were raised and the agency asked for more information. Cytomedix said it sent the requested information, and was notified Friday of the FDA's position.

"We are very disappointed with this decision. We continue to believe, based on the safety and effectiveness information that we have submitted, that our product merits marketing clearance by the FDA. We will work through the appeal process as expeditiously as possible," said K****ij Mohan, chairman and CEO.

Cytomedix will hold a conference call to discuss the matter at 4 p.m. Eastern time.

Shares closed Monday at $2.75 on the American Stock Exchange.

--------------------
Best Regards and Good Trading

Posts: 239 | From: Florida City, FL | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share